explore -WSS

explore

author：hotspot 2025-10-01 20:15:06 - browse：7

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

explore

WSS

Boston hospital trains restaurant workers on naloxone for overdoses

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Boston hospital trains restaurant workers on naloxone for overdoses

Hospitals are piloting generative AI tools as regulators play catch

Reporting on presidential health from Reagan to Trump and Biden

STAT reporters are Pulitzer Prize finalists for investigative reporting

focus

explore

hotspot

Medical records are filled with copy

Novo Nordisk testing Wegovy against alcohol

Virginia high school admissions case could be legal follow

Novo Nordisk testing Wegovy against alcohol

In Memoriam: Notable people who died in 2023

Researchers tackle phage therapy hurdles for wider adoption

Cancer drug shortages should be causing more outrage

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

What does generative AI mean for health care? We asked experts

Fertility clinic egg and embryo storage is a disaster

knowledge

Supreme Court to hear if Covid misinformation is protected speech

Abridge raises $150m as clinical notes automation market heats up

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Fertility clinic egg and embryo storage is a disaster

Ukraine seeks to reclaim its role as a hub for clinical trials

entertainment

explore

knowledge

focus